The recent success of targeting tyrosine kinaseactivity linked to specific receptors for several major growth factors –platelet-derived growth factor (PDGF), VEGF, fibroblast growth factor (FGF) andcolony stimulating factor 1 (CSF1), as well as Src family kinases for treatment of ILD.118 Initial trials were in IPF, but more recently, nintedanib was shown to have amajor effect on progressive lung fibrosis of other causes. This evidence concerns the gene CSF1 and idiopathic pulmonary fibrosis.